Latest Post

BioNext Technology Review: Latest post

Protein Biomarkers Part I: Fact versus Fiction

  Preface to Biomarkers Its difficult to know where to begin when discussing the nascent biotechnological sector known as Biomarkers. I think therefore it may be helpful for the uninitiated to give the term some context and definition. In its simplest definition, a biomarker is any substance which is used as an indicator of a biologic, [...]

Asides

  • Writers wanted! Come and join us! We are looking for people to post, cross post, or just hang out on our forums and chat about bioscience biobusiness and anything else bio. #

Welcome to BioNext Technology Review

In this evolution of the industry, adaptive advantage is bestowed upon those who understand that real intellectual capital of the Pharmaceutical and Biotechnology industries is an understanding of disease.

Recent Posts

Cougar Biotechnology: Stalking Prostate Cancer
Cougar Biotechnology: Stalking Prostate Cancer
July 1, 2008
By Bryan
Why VC backed deals are in the safe zone
Why VC backed deals are in the safe zone
May 7, 2008
By Dusan Bogunovic
Cancer Vaccines - Dendritic Cells
Cancer Vaccines - Dendritic Cells
February 14, 2008
By Dusan Bogunovic
Aegerion: Capitalizing on Cholesterol
Aegerion: Capitalizing on Cholesterol
February 11, 2008
By Bryan
Targanta Therapeutics Part III : To Buy or Not?
Targanta Therapeutics Part III : To Buy or Not?
January 29, 2008
By drewaight
Targanta Therapeutics Part II : Oritavancin
Targanta Therapeutics Part II : Oritavancin
January 29, 2008
By drewaight
Targanta Therapeutics Part I : Antimicrobial Resistance
Targanta Therapeutics Part I : Antimicrobial Resistance
January 29, 2008
By drewaight
Alzheimer’s Disease: Treatments and Cures
Alzheimer’s Disease: Treatments and Cures
January 16, 2008
By FutureBen
Biolex: A preview and a pulled IPO
Biolex: A preview and a pulled IPO
December 3, 2007
By drewaight
Biologics Biopharmaceuticals and Protein Therapeutics Part II: Biomanufacturing
Biologics Biopharmaceuticals and Protein Therapeutics Part II: Biomanufacturing
December 3, 2007
By drewaight
Biologics Biopharmaceuticals and Protein Therapeutics Part I: The state of the Sector
Biologics Biopharmaceuticals and Protein Therapeutics Part I: The state of the Sector
December 3, 2007
By drewaight
Interview with Helicos COO Steve Lombardi
December 3, 2007
By drewaight
Helicos part III
December 3, 2007
By drewaight
Helicos part II
December 3, 2007
By drewaight
Helicos part I
December 3, 2007
By drewaight